Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

The interaction of programmed cell death 1 ligand 1 (PDL1) with its receptor programmed
cell death 1 (PD1) inhibits T cell responses, and blockade of this interaction has proven to …

Pyroptosis has been reported to improve the immunosuppressive tumor microenvironment
and may be a strategy to enhance osteosarcoma treatment. The extent to which modulation …

Extracellular vesicles (EVs) are nano-sized, membranous structures secreted into the
extracellular space. They exhibit diverse sizes, contents, and surface markers and are …

Hypoxia is a remarkable trait of the tumor microenvironment (TME). When facing selective
pressure, tumor cells show various adaptive characteristics, such as changes in the …

Gastric cancer (GC) is a high-incidence cancer worldwide. Most patients are diagnosed at
an advanced stage, by which time they have limited treatment options and poor prognosis …

Tumor-derived extracellular vesicles (TEVs) suppress the proliferation and cytotoxicity of
CD8+ T cells, thereby contributing to tumor immune evasion. Here, we report that the …

Macrophages play a pivotal role in tumor immunity. We report that reprogramming of
macrophages to tumor-associated macrophages (TAMs) promotes the secretion of …

Abstract Purpose: This phase Ib/2 trial investigated pembrolizumab-containing trimodality
therapy in patients with gastroesophageal junction (GEJ) adenocarcinoma. Patients and …

Extracellular vesicles (EVs) carrying tumor cell-derived programmed death-ligand 1 (PD-L1)
interact with programmed death 1 (PD-1)-producing T cells, thus significantly lowering a …